HC Wainwright Reiterates Buy Rating for TransCode Therapeutics (NASDAQ:RNAZ)

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 68.18% from the company’s previous close.

TransCode Therapeutics Stock Performance

NASDAQ RNAZ traded up $2.95 on Thursday, reaching $11.89. The stock had a trading volume of 11,597,825 shares, compared to its average volume of 3,996,321. The business has a 50 day moving average price of $32.08 and a 200 day moving average price of $295.96. TransCode Therapeutics has a 1 year low of $2.66 and a 1 year high of $66.33.

Institutional Trading of TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management increased its holdings in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 50,138 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Sheets Smith Wealth Management owned approximately 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent reporting period.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.